| Literature DB >> 35631434 |
Puji Astuti1,2,3,4, Khairan Khairan4,5,6,7, Marthoenis Marthoenis8, Kartini Hasballah9.
Abstract
Essential oils are gaining popularity for their use in treating depression, including that extracted from patchouli leaves and stems (Pogostemon cablin). Herein, we used patchouli oil (PO) containing a high amount of patchouli alcohol derived from P. cablin var. Tapak Tuan. The aim of this study was to investigate the antidepressant potential of PO, with a variety of patchouli alcohol concentrations obtained from a separation process using vacuum distillation with different temperature ranges. The initial patchouli oil (iPO) was traditionally distilled by a local farmer and further distilled using a rotary evaporator at temperature ranges of 115-160 °C (POF-1); 120-160 °C (POF-2), and 125-160 °C (POF-3), resulting in products with different patchouli alcohol concentrations. POF-3, with the highest patchouli alcohol content of 60.66% (based on gas chromatography-mass spectrometry), was used for cooling crystallization, resulting in 100% patchouli alcohol crystal (pPA). A tail suspension test (TST) was performed on a rat model to screen the antidepressant potential of iPO and its derivatives. The TST results revealed that POF-3 had the best antidepressant-like effect and was second only to the fluoxetine-based antidepressant, Kalxetin®, where both groups had significant reductions of immobility time post-treatment (p < 0.0001). Other than patchouli alcohol, POF-3 also contained ledol and trans-geraniol, which have been reported for their antidepressant-related activities. Brain dopamine levels increased significantly in the group treated with POF-3 (p < 0.05 as compared with the control group), suggesting its primary anti-depressant mechanism. These findings suggest the potential of vacuum-distilled patchouli oil in reducing depression via dopamine elevation.Entities:
Keywords: cortisol; dopamine; patchoulol; serotonin; tail suspension
Year: 2022 PMID: 35631434 PMCID: PMC9145128 DOI: 10.3390/ph15050608
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Results from GC-MS analysis on iPO, POFs, and pPA.
| Chemical Compounds | Percentage of Area (%) | ||||
|---|---|---|---|---|---|
| iPO | POF-1 | POF-2 | POF-3 | pPA | |
| Patchouli alcohol | 28.68 | 42.81 | 49.29 | 60.66 | 100 |
| δ-Guaiene | 24.87 | 25.56 | 27.51 | - | - |
| Ledol | - | - | - | 21.54 | |
| α-Guaiene | 16.89 | 8.73 | 4.58 | - | - |
| Seychellene | 8.32 | 3.99 | 0.91 | 1.71 | - |
| γ-Elemene | - | - | - | 7.83 | |
| α-Patchoulene | 7.29 | - | - | 1.43 | - |
| β-Patchoulene | 5.05 | - | - | - | - |
| (-)-Globulol | - | 5.77 | 6.42 | - | |
| Champacol | - | 3.05 | 1.53 | - | - |
| Globulol | 2.94 | - | 1.85 | - | - |
| α-Gurjunene | - | - | - | 2.54 | - |
| α-Selinene | - | - | - | 2.00 | - |
| Caryophyllene | 1.99 | - | 0.78 | - | - |
| 8-Isopropenyl-1,5-dimethyl-cyclodeca-1,5-diene | - | 1.78 | - | - | - |
| But-3-enal, 2-methyl-4-(2,6,6-trimethyl-1-cyclohexenyl)- | - | 1.75 | 1.96 | - | - |
| Aromadendrene, dehydro- | - | 1.48 | 1.23 | - | - |
| (-)-β-Elemene | - | - | - | 1.25 | - |
| 2,3,3-Trimethyl-2-(3-methyl-buta-1,3- dienyl)-cyclohexanone | 1.10 | - | - | - | - |
| Longipinocarveol, trans- | 1.08 | - | 2.34 | - | - |
| trans-Geraniol | - | - | - | 1.05 | |
| (-)-Globulol | 0.82 | 1.81 | - | - | - |
| (-)-Spathulenol | 0.41 | 1.95 | - | - | - |
| 2-Methyl-3-isopropenylcyclohexanol | 0.34 | 0.50 | 0.60 | - | - |
| 2(1H)Naphthalenone, 3,5,6,7,8,8a- hexahydro-4,8a-dimethyl-6-(1- methylethenyl)- | 0.22 | 0.43 | 0.45 | - | - |
| Selina-6-en-4-ol | - | 0.39 | 0.55 | - | - |
(-) indicates the absence of the compound.
Figure 1GC-MS chromatogram of iPO (a), POF-1 (b), POF-2 (c), POF-3 (d), and (pPA) (e).
Figure 2Rat’s immobility time observed during the TST, pre- and post-treatment. * significant at p < 0.05, ** significant at p < 0.01, and *** significant at p < 0.001 based on unpaired t-test with Welch’s correction.
Level of plasma cortisol and brain serotonin and dopamine (n = 32).
| Group | Cortisol | Serotonin | Dopamine | |||
|---|---|---|---|---|---|---|
| Level, Mean ± SD (ng/mL) | Level, Mean ± SD (ng/mL) | Level, Mean ± SD (ng/mL) | ||||
| Normal | 23.32 ± 2.27 | NA | 22.84 ± 4.36 | NA | 220.98 ± 2.36 | NA |
| Control | 121.61 ± 30.54 | ## 0.0073 | 20.72 ± 1.74 | 0.4177 | 182.24 ± 9.51 | ## 0.0025 |
| Kalxetin® | 169.49 ± 24.59 | 0.0522 | 17.14 ± 1.02 | * 0.0172 | 191.54 ± 15.79 | 0.3600 |
| iPO | 99.85 ± 27.35 | 0.3296 | 23.80 ± 3.66 | 0.1976 | 211.71 ± 17.93 | * 0.0374 |
| POF-1 | 153.98 ± 125.98 | 0.6485 | 20.88 ± 2.04 | 0.9103 | 192.86 ± 15.92 | 0.3049 |
| POF-2 | 196.69 ± 22.52 | 0.5544 | 17.68 ± 0.90 | * 0.0309 | 133.55 ± 5.88 | * 0.0492 |
| POF-3 | 81.27 ± 45.02 | 0.1951 | 23.71 ± 2.01 | 0.0662 | 223.36 ± 19.18 | * 0.0155 |
| pPA | 123.58 ± 41.20 | 0.9415 | 24.43 ± 4.12 | 0.1718 | 215.62 ± 28.45 | 0.0962 |
NA: Not applicable. ## Very statistically significant as compared with normal group (p < 0.01). * Statistically significant as compared with control group (p < 0.05). All comparative analyses were based on unpaired t-test with Welch’s correction.
Scheme 1Fractionation of initial patchouli oil (iPO), and its purification into purified patchouli alcohol (pPA) crystal.